EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Novel hydrazone‐isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling

Marwa F Ahmed, Radwan El-Haggar, Atiah H Almalki, Omeima Abdullah, Mahmoud A El Hassab, Nicolas Masurier, Sherif F Hammad

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202300244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Marwa F Ahmed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia. Hauptthemen laut MEDLINE: Hydrazones, Antineoplastic Agents, Isatin, Protein Kinase Inhibitors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deanship of Scientific Research, Taif University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Merging isatin and arylhydrazone moieties constitutes an efficient strategy to access new potential anticancer derivatives. Consequently, 14 hydrazone‐isatin derivatives were synthesized and evaluated for their antiproliferative activity against the NCI‐60 cancer cell line panel. A kinase assay demonstrated that compound VIIIb inhibited the epidermal growth factor receptor (EGFR), which was confirmed by docking studies, molecular dynamics, and binding free energy calculations. Further characterizations showed that this compound possesses drug‐likeness properties, showed a significant decrease of the cell population in the G2/M phase and led to a significant increase in early and late apoptosis, comparable to erlotinib. Also, VIIIb increased the expression of caspase‐3 and Bax and decreased the expression of Bcl‐2, confirming its potential as a new proapoptotic compound.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrazonesAntineoplastic AgentsIsatinProtein Kinase InhibitorsHumansErbB ReceptorsStructure-Activity RelationshipApoptosisCell ProliferationCell Line, TumorDrug Screening Assays, AntitumorMolecular StructureMolecular Docking SimulationDose-Response Relationship, DrugMolecular Dynamics Simulation

Stichwörter der Autor:innen

EGFRanticancerbreast cancerhydrazoneisatin

Substanzen

ErbB ReceptorsHydrazonesAntineoplastic AgentsIsatinEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Ain Helwan, Egypt.
  • Addition and Neuroscience Research Unit, College of Pharmacy, Taif University, Taif, Al-Hawiah, Saudi Arabia.
  • Pharmaceutical Chemistry Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, Egypt.
  • Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France.

Förderung

  • Deanship of Scientific Research, Taif University

Zitieren

APA

Ahmed, M. F., El-Haggar, R., Almalki, A. H., Abdullah, O., El Hassab, M. A., Masurier, N., & Hammad, S. F. (2023). Novel hydrazone‐isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300244

Vancouver

Ahmed MF, El-Haggar R, Almalki AH, Abdullah O, El Hassab MA, Masurier N, et al. Novel hydrazone‐isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300244

BibTeX
@article{Ahmed2023,
  author = {Ahmed, Marwa F and El-Haggar, Radwan and Almalki, Atiah H and Abdullah, Omeima and El Hassab, Mahmoud A and Masurier, Nicolas and Hammad, Sherif F},
  title = {Novel hydrazone‐isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202300244}
}
Kostenlos starten →